Abiraterone Acetate: From CYP17 to 3D Models
2026-08-19
A translational framework for using Abiraterone acetate as a CYP17 inhibitor, interpreting its biology in patient-derived prostate cancer spheroids, and designing more informative mechanistic assays.
S Tag Peptide (A6007): Workflow Guide
2026-08-19
S Tag Peptide is a soluble 15-amino-acid tag for recombinant protein detection, antibody-based purification, and protein solubility improvement when genetically fused to a target protein. It is not suitable for ethanol-based workflows, prolonged solution storage, or applications that require the tag to fold independently into a defined structure.
Phosphatase Inhibitor Cocktail 1: Assay Design
2026-08-18
Phosphatase Inhibitor Cocktail 1 can protect labile phosphorylation signals during lysate preparation. This article connects inhibitor selection to heterogeneous BET responses in HPV-associated cancer and provides a decision-focused workflow for reliable assays.
ECL Western Blotting Substrate: Practical Guide
2026-08-18
ECL Western Blotting Substrate (SKU K2187) is a luminol-based, nonradioactive horseradish peroxidase detection reagent for Western blot assays requiring chemiluminescent imaging, clear background, and flexible exposure control. It is intended for HRP-based immunoblotting and should not be substituted for fluorescent or radioisotopic detection workflows.
ERK5 and Vitamin D–Induced AML Differentiation
2026-08-17
Wang et al. identify the MEK5–ERK5 pathway as a distinct regulator of 1α,25-dihydroxyvitamin D3-induced differentiation in HL60 and U937 myeloid leukemia cells. Their inhibitor-based experiments show that ERK5 suppression enhances some differentiation features while imposing cell-cycle arrest, whereas MEK1/2–ERK1/2 inhibition broadly weakens the differentiation response.
Epigenetic MCL-1 Targeting in Glioblastoma
2026-08-16
The reference study identifies a super-enhancer near Mcl-1 as a transcriptional vulnerability in glioblastoma and shows that disrupting this locus with THZ1 sensitizes tumors to BCL-2/BCL-XL inhibition. Its combined chromatin, mitochondrial apoptosis, and patient-derived xenograft data support a model of context-dependent synthetic lethality, while also defining important limits for translating the findings to pharmacological workflows.
TAK-242 (Resatorvid) TLR4 Assay Guide
2026-08-15
Build cleaner LPS-response experiments with TAK-242 (Resatorvid), from dose-ranging macrophage assays to mechanistic studies of microbiota-derived immune signals. This practical guide emphasizes pathway-specific controls, stock handling, neuroinflammation applications, and the important distinction between suppressing TLR4 activity and improving an immune-therapy outcome.
Z-VAD-FMK: Rethinking Apoptosis Under Energy Stress
2026-08-15
Energy stress, autophagy, and apoptosis are often studied as separate programs, yet recent evidence shows that caspase activity can influence whether autophagy machinery remains available for recovery. This thought-leadership guide explains how Z-VAD-FMK can help translational researchers test caspase dependence, interpret apoptosis inhibition data, and design more informative studies in immune and cancer models.
BMS-777607 in iPSC Platelet Research
2026-08-14
Explore how BMS-777607, a selective c-Met inhibitor, can be evaluated as a mechanistic perturbation in iPSC-derived megakaryocyte and platelet studies. This article distinguishes oncology evidence from platelet-production findings and translates both into rigorous assay decisions.
Sulfo-NHS-Biotin for Surface Labeling and PLI
2026-08-13
Sulfo-NHS-Biotin enables fast, aqueous labeling of primary amines for cell-surface proteomics, affinity capture, and immunoprecipitation workflows. This guide also shows how its capture chemistry could complement phage-layer interferometry while clearly separating established product use from exploratory assay design.
EZH2 Inhibition and 5-Azacytidine in PTEN-Deficient GBM
2026-08-13
The 2025 reference study shows that PTEN-deficient glioblastoma suppresses ERV-MAVS-IFN signaling and thereby maintains an immunosuppressive tumor microenvironment. EZH2 inhibition restored the activity of 5-Azacytidine by reducing H3K27me3-mediated repression of endogenous retroviruses, producing stronger viral mimicry, type I interferon signaling, and antitumor immune activity.
ATRX-Deficient Glioma and RTK Inhibitor Sensitivity
2026-08-13
The reference study identifies ATRX deficiency as a potential biomarker of increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data further suggest that ATRX status may influence responses to RTK inhibitor–temozolomide treatment, although clinical translation remains unproven.
DCFH-DA for Intracellular ROS Assays
2026-08-12
2,7-Dichlorodihydrofluorescein diacetate, also known as DCFH-DA, converts intracellular redox changes into a measurable green fluorescence signal. This guide translates the probe into practical microscopy, flow cytometry, and plate-based workflows, with specific considerations for fibroblast fibrosis and autophagy studies.
MRE11 Lactylation Drives TNBC Radioresistance
2026-08-12
The reference study identifies lactate-dependent MRE11 Lys673 lactylation as a DNA-repair mechanism that supports radiotherapy resistance in triple-negative breast cancer. It further shows that Saikosaponin D activates an HIF1α/HDAC5 pathway to remove this modification, providing a preclinical rationale for targeting metabolic–epigenetic control of radioresistance.
6-Thioguanine Inhibits EV71 via BIRC3 Autophagy
2026-08-11
The 2025 BMC Microbiology study identifies 6-thioguanine as an inhibitor of EV71 replication in HT-29 cells and links this activity to reduced BIRC3-mediated complete autophagy. Its high in vitro selectivity index supports further antiviral investigation, while the cell-based design and lack of clinical validation require cautious interpretation.
460 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page